Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also focuses on immunology, human genetics, and advanced technologies to deliver transformational new medicines for patients. The Company's research and development focuses on developing vaccines against infectious diseases that combine high medical needs and market potential. The Company's Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, minerals and supplements. It provides prescription medicines, vaccines, and consumer healthcare products.

  • Revenue in GBP (TTM)36.48bn
  • Net income in GBP5.11bn
  • Incorporated1999
  • Employees90.10k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 208 047 5000
  • Fax+44 208 047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GSK:LSE since
announced
Transaction
value
Affinivax IncAnnounced31 May 202231 May 2022Announced1.63%3.30bn
Sierra Oncology IncAnnounced13 Apr 202213 Apr 2022Announced-1.55%2.08bn
Data delayed at least 20 minutes, as of Jun 24 2022 16:45 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lonza Group AG4.60bn573.70m32.50bn16.22k56.673.9032.847.069.0539.5472.61131.420.35022.506.58333,518.304.385.005.366.1439.0139.8212.5213.971.8817.420.196631.4019.995.53-7.6717.4929.663.33
GSK plc36.48bn5.11bn89.29bn90.10k17.395.5210.242.451.011.017.203.180.43482.074.93404,857.007.166.9610.8511.6165.2968.4816.4614.680.946711.640.595694.830.0444.11-23.7336.904.500.00
Sanofi SA34.72bn5.74bn109.51bn95.44k18.97--15.333.155.305.3032.15--------422,686.00--5.19--6.2369.1468.0616.5015.36--31.63--66.944.832.46-49.387.20-0.3872.28
Novo Nordisk A/S17.24bn5.71bn158.47bn49.30k36.6626.8924.949.1921.4521.4564.7429.240.88051.274.643,118,242.0029.1532.6557.8763.1283.3883.7933.1133.520.69335.930.276950.1810.914.7213.334.72-2.236.47
AstraZeneca plc33.83bn-866.91m166.94bn83.10k--5.6334.214.93-0.5412-0.541222.8419.130.50231.915.54407,146.70-1.282.62-1.753.6672.6178.90-2.556.610.66064.970.461196.2640.5810.22-96.50-49.76-1.011.03
Data as of Jun 24 2022. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX

Institutional shareholders

18.85%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 May 2022161.81m3.18%
BlackRock Fund Advisorsas of 03 Mar 2021131.21m2.58%
Dodge & Coxas of 31 Dec 2021117.97m2.32%
Norges Bank Investment Managementas of 01 May 2022112.09m2.21%
Schroder Investment Management Ltd.as of 01 May 202288.52m1.74%
Capital Research & Management Co. (Global Investors)as of 01 May 202276.72m1.51%
Legal & General Investment Management Ltd.as of 01 May 202274.32m1.46%
BlackRock Advisors (UK) Ltd.as of 01 May 202272.92m1.43%
Silchester International Investors LLPas of 01 May 202266.61m1.31%
Mondrian Investment Partners Ltd.as of 01 May 202255.96m1.10%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.